View Financial HealthPyridam Farma 배당 및 자사주 매입배당 기준 점검 0/6Pyridam Farma 현재 배당금을 지급하지 않습니다.핵심 정보0%배당 수익률-0.0004%자사주 매입 수익률총 주주 수익률-0.0004%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향0%최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesReported Earnings • Jun 04First quarter 2026 earnings released: Rp7.20 loss per share (vs Rp8.15 loss in 1Q 2025)First quarter 2026 results: Rp7.20 loss per share (improved from Rp8.15 loss in 1Q 2025). Revenue: Rp766.5b (up 12% from 1Q 2025). Net loss: Rp80.9b (loss narrowed 11% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-Rp533b free cash flow). Earnings have declined by 61% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).공시 • May 06PT Pyridam Farma Tbk, Annual General Meeting, Jun 11, 2026PT Pyridam Farma Tbk, Annual General Meeting, Jun 11, 2026.Reported Earnings • Apr 04Full year 2025 earnings released: Rp33.79 loss per share (vs Rp38.91 loss in FY 2024)Full year 2025 results: Rp33.79 loss per share. Revenue: Rp2.76t (up 44% from FY 2024). Net loss: Rp379.7b (loss widened 15% from FY 2024).Reported Earnings • Nov 04Third quarter 2025 earnings released: Rp12.21 loss per share (vs Rp10.71 loss in 3Q 2024)Third quarter 2025 results: Rp12.21 loss per share (further deteriorated from Rp10.71 loss in 3Q 2024). Revenue: Rp674.8b (down 11% from 3Q 2024). Net loss: Rp152.6b (loss widened 27% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance.Board Change • Oct 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • May 12PT Pyridam Farma Tbk, Annual General Meeting, Jun 18, 2025PT Pyridam Farma Tbk, Annual General Meeting, Jun 18, 2025.Reported Earnings • Nov 03Third quarter 2024 earnings released: Rp10.72 loss per share (vs Rp16.47 loss in 3Q 2023)Third quarter 2024 results: Rp10.72 loss per share. Revenue: Rp754.5b (up 265% from 3Q 2023). Net loss: Rp120.4b (loss widened Rp111.6b from 3Q 2023).New Risk • Oct 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Shareholders have been substantially diluted in the past year (over 20x increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change).공시 • May 21PT Pyridam Farma Tbk, Annual General Meeting, Jun 25, 2024PT Pyridam Farma Tbk, Annual General Meeting, Jun 25, 2024.New Risk • May 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 20x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (over 20x increase in shares outstanding). Minor Risk Market cap is less than US$100m (Rp1.18t market cap, or US$74.3m).New Risk • Apr 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: Rp87.8b (US$5.44m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Share price has been highly volatile over the past 3 months (27% average weekly change). Market cap is less than US$10m (Rp87.8b market cap, or US$5.44m).Reported Earnings • Mar 16Full year 2023 earnings released: Rp159 loss per share (vs Rp515 profit in FY 2022)Full year 2023 results: Rp159 loss per share (down from Rp515 profit in FY 2022). Revenue: Rp702.1b (down 1.9% from FY 2022). Net loss: Rp85.2b (down 131% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.공시 • Jan 11PT Pyridam Farma Tbk has filed a Follow-on Equity Offering.PT Pyridam Farma Tbk has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 16,000,000,000 Transaction Features: Rights OfferingNew Risk • Nov 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$100m (Rp524.4b market cap, or US$33.9m).Reported Earnings • Aug 06Second quarter 2023 earnings released: Rp45.55 loss per share (vs Rp12.25 profit in 2Q 2022)Second quarter 2023 results: Rp45.55 loss per share (down from Rp12.25 profit in 2Q 2022). Revenue: Rp148.8b (up 11% from 2Q 2022). Net loss: Rp24.4b (down 472% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.New Risk • Jun 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.4% operating cash flow to total debt). High level of non-cash earnings (30% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (Rp457.5b market cap, or US$30.5m).Reported Earnings • May 08First quarter 2023 earnings released: Rp23.01 loss per share (vs Rp4.67 profit in 1Q 2022)First quarter 2023 results: Rp23.01 loss per share (down from Rp4.67 profit in 1Q 2022). Revenue: Rp164.9b (down 4.4% from 1Q 2022). Net loss: Rp12.3b (down Rp14.8b from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 08Full year 2022 earnings releasedFull year 2022 results: Revenue: Rp715.4b (up 14% from FY 2021). Net income: Rp275.5b (up Rp270.0b from FY 2021). Profit margin: 39% (up from 0.9% in FY 2021). The increase in margin was primarily driven by lower expenses.Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 2 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Independent Commissioner Mohammad Arifin is the most experienced director on the board, commencing their role in 2015. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Sep 05Second quarter 2022 earnings released: EPS: Rp12.25 (vs Rp0.96 in 2Q 2021)Second quarter 2022 results: EPS: Rp12.25 (up from Rp0.96 in 2Q 2021). Revenue: Rp134.7b (up 28% from 2Q 2021). Net income: Rp6.56b (up Rp6.04b from 2Q 2021). Profit margin: 4.9% (up from 0.5% in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 79% per year, which means it is well ahead of earnings.Board Change • Apr 27Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Commissioner Mohammad Arifin is the most experienced director on the board, commencing their role in 2015. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.공시 • Aug 28PT Pyridam Farma Tbk (IDX:PYFA) entred into an agreement to acquire PT Holi Pharma from Erik Darius Mardiwidyo and Murtiati.PT Pyridam Farma Tbk (IDX:PYFA) entred into an agreement to acquire PT Holi Pharma from Erik Darius Mardiwidyo and Murtiation August 23, 2021.Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 25% share price gain to Rp1,240, the stock trades at a trailing P/E ratio of 30x. Average forward P/E is 22x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 611% over the past three years.Reported Earnings • Jul 04Full year 2020 earnings released: EPS Rp41.31 (vs Rp17.46 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: Rp277.4b (up 12% from FY 2019). Net income: Rp22.1b (up 137% from FY 2019). Profit margin: 8.0% (up from 3.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improved over the past weekAfter last week's 24% share price gain to Rp1,200, the stock trades at a trailing P/E ratio of 31.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 538% over the past three years.Valuation Update With 7 Day Price Move • Apr 30Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,235, the stock trades at a trailing P/E ratio of 32.2x. Average trailing P/E is 25x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 531% over the past three years.Valuation Update With 7 Day Price Move • Jan 18Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to Rp1,120, the stock is trading at a trailing P/E ratio of 29.2x, down from the previous P/E ratio of 38.6x. This compares to an average P/E of 24x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 472%.Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,340, the stock is trading at a trailing P/E ratio of 34.9x, up from the previous P/E ratio of 29.8x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 605%.Is New 90 Day High Low • Jan 11New 90-day high: Rp1,340The company is up 38% from its price of Rp970 on 14 October 2020. The Indonesian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,145, the stock is trading at a trailing P/E ratio of 29.8x, up from the previous P/E ratio of 25.4x. This compares to an average P/E of 21x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 479%.Valuation Update With 7 Day Price Move • Dec 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to Rp1,035, the stock is trading at a trailing P/E ratio of 27x, down from the previous P/E ratio of 31.8x. This compares to an average P/E of 22x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 481%.Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 30% share price gain to Rp1,150, the stock is trading at a trailing P/E ratio of 30x, up from the previous P/E ratio of 23.1x. This compares to an average P/E of 20x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 518%.Is New 90 Day High Low • Dec 08New 90-day high: Rp1,150The company is up 44% from its price of Rp800 on 09 September 2020. The Indonesian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 2.0% over the same period.Reported Earnings • Nov 08Third quarter 2020 earnings released: EPS Rp19.49The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: Rp73.7b (up 16% from 3Q 2019). Net income: Rp10.4b (up 230% from 3Q 2019). Profit margin: 14% (up from 5.0% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Oct 15Market bids up stock over the past weekAfter last week's 23% share price gain to Rp970, the stock is trading at a trailing P/E ratio of 39.1x, up from the previous P/E ratio of 31.8x. This compares to an average P/E of 15x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 413%.공시 • Aug 04PT Pyridam Internasional Corporation acquired additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih for approximately IDR 120 billion.PT Pyridam Internasional Corporation acquired additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih for approximately IDR 120 billion on July 10, 2020. PT Pyridam Internasional acquired 160.3 million shares at an offer per share IDR 770.91. Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih sold 36.81 million shares, 61.74 million shares and 61.74 million shares respectively. PT Pyridam Internasional Corporation completed the acquisition of additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih on July 10, 2020.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 PYFA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: PYFA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Pyridam Farma 배당 수익률 vs 시장PYFA의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (PYFA)0%시장 하위 25% (ID)1.2%시장 상위 25% (ID)6.8%업계 평균 (Pharmaceuticals)4.9%분석가 예측 (PYFA) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PYFA 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PYFA 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: PYFA ID 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: PYFA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YID 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/25 07:30종가2026/06/25 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PT Pyridam Farma Tbk는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Elvira NataliaPT Sinarmas Sekuritas
Reported Earnings • Jun 04First quarter 2026 earnings released: Rp7.20 loss per share (vs Rp8.15 loss in 1Q 2025)First quarter 2026 results: Rp7.20 loss per share (improved from Rp8.15 loss in 1Q 2025). Revenue: Rp766.5b (up 12% from 1Q 2025). Net loss: Rp80.9b (loss narrowed 11% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.
New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-Rp533b free cash flow). Earnings have declined by 61% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).
공시 • May 06PT Pyridam Farma Tbk, Annual General Meeting, Jun 11, 2026PT Pyridam Farma Tbk, Annual General Meeting, Jun 11, 2026.
Reported Earnings • Apr 04Full year 2025 earnings released: Rp33.79 loss per share (vs Rp38.91 loss in FY 2024)Full year 2025 results: Rp33.79 loss per share. Revenue: Rp2.76t (up 44% from FY 2024). Net loss: Rp379.7b (loss widened 15% from FY 2024).
Reported Earnings • Nov 04Third quarter 2025 earnings released: Rp12.21 loss per share (vs Rp10.71 loss in 3Q 2024)Third quarter 2025 results: Rp12.21 loss per share (further deteriorated from Rp10.71 loss in 3Q 2024). Revenue: Rp674.8b (down 11% from 3Q 2024). Net loss: Rp152.6b (loss widened 27% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance.
Board Change • Oct 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • May 12PT Pyridam Farma Tbk, Annual General Meeting, Jun 18, 2025PT Pyridam Farma Tbk, Annual General Meeting, Jun 18, 2025.
Reported Earnings • Nov 03Third quarter 2024 earnings released: Rp10.72 loss per share (vs Rp16.47 loss in 3Q 2023)Third quarter 2024 results: Rp10.72 loss per share. Revenue: Rp754.5b (up 265% from 3Q 2023). Net loss: Rp120.4b (loss widened Rp111.6b from 3Q 2023).
New Risk • Oct 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Shareholders have been substantially diluted in the past year (over 20x increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change).
공시 • May 21PT Pyridam Farma Tbk, Annual General Meeting, Jun 25, 2024PT Pyridam Farma Tbk, Annual General Meeting, Jun 25, 2024.
New Risk • May 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 20x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (over 20x increase in shares outstanding). Minor Risk Market cap is less than US$100m (Rp1.18t market cap, or US$74.3m).
New Risk • Apr 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: Rp87.8b (US$5.44m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Share price has been highly volatile over the past 3 months (27% average weekly change). Market cap is less than US$10m (Rp87.8b market cap, or US$5.44m).
Reported Earnings • Mar 16Full year 2023 earnings released: Rp159 loss per share (vs Rp515 profit in FY 2022)Full year 2023 results: Rp159 loss per share (down from Rp515 profit in FY 2022). Revenue: Rp702.1b (down 1.9% from FY 2022). Net loss: Rp85.2b (down 131% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
공시 • Jan 11PT Pyridam Farma Tbk has filed a Follow-on Equity Offering.PT Pyridam Farma Tbk has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 16,000,000,000 Transaction Features: Rights Offering
New Risk • Nov 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$100m (Rp524.4b market cap, or US$33.9m).
Reported Earnings • Aug 06Second quarter 2023 earnings released: Rp45.55 loss per share (vs Rp12.25 profit in 2Q 2022)Second quarter 2023 results: Rp45.55 loss per share (down from Rp12.25 profit in 2Q 2022). Revenue: Rp148.8b (up 11% from 2Q 2022). Net loss: Rp24.4b (down 472% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
New Risk • Jun 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.4% operating cash flow to total debt). High level of non-cash earnings (30% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (Rp457.5b market cap, or US$30.5m).
Reported Earnings • May 08First quarter 2023 earnings released: Rp23.01 loss per share (vs Rp4.67 profit in 1Q 2022)First quarter 2023 results: Rp23.01 loss per share (down from Rp4.67 profit in 1Q 2022). Revenue: Rp164.9b (down 4.4% from 1Q 2022). Net loss: Rp12.3b (down Rp14.8b from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 08Full year 2022 earnings releasedFull year 2022 results: Revenue: Rp715.4b (up 14% from FY 2021). Net income: Rp275.5b (up Rp270.0b from FY 2021). Profit margin: 39% (up from 0.9% in FY 2021). The increase in margin was primarily driven by lower expenses.
Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 2 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Independent Commissioner Mohammad Arifin is the most experienced director on the board, commencing their role in 2015. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Sep 05Second quarter 2022 earnings released: EPS: Rp12.25 (vs Rp0.96 in 2Q 2021)Second quarter 2022 results: EPS: Rp12.25 (up from Rp0.96 in 2Q 2021). Revenue: Rp134.7b (up 28% from 2Q 2021). Net income: Rp6.56b (up Rp6.04b from 2Q 2021). Profit margin: 4.9% (up from 0.5% in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 79% per year, which means it is well ahead of earnings.
Board Change • Apr 27Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Commissioner Mohammad Arifin is the most experienced director on the board, commencing their role in 2015. Independent Commissioner Charles Marpaung was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • Aug 28PT Pyridam Farma Tbk (IDX:PYFA) entred into an agreement to acquire PT Holi Pharma from Erik Darius Mardiwidyo and Murtiati.PT Pyridam Farma Tbk (IDX:PYFA) entred into an agreement to acquire PT Holi Pharma from Erik Darius Mardiwidyo and Murtiation August 23, 2021.
Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 25% share price gain to Rp1,240, the stock trades at a trailing P/E ratio of 30x. Average forward P/E is 22x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 611% over the past three years.
Reported Earnings • Jul 04Full year 2020 earnings released: EPS Rp41.31 (vs Rp17.46 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: Rp277.4b (up 12% from FY 2019). Net income: Rp22.1b (up 137% from FY 2019). Profit margin: 8.0% (up from 3.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improved over the past weekAfter last week's 24% share price gain to Rp1,200, the stock trades at a trailing P/E ratio of 31.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 538% over the past three years.
Valuation Update With 7 Day Price Move • Apr 30Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,235, the stock trades at a trailing P/E ratio of 32.2x. Average trailing P/E is 25x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 531% over the past three years.
Valuation Update With 7 Day Price Move • Jan 18Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to Rp1,120, the stock is trading at a trailing P/E ratio of 29.2x, down from the previous P/E ratio of 38.6x. This compares to an average P/E of 24x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 472%.
Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,340, the stock is trading at a trailing P/E ratio of 34.9x, up from the previous P/E ratio of 29.8x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 605%.
Is New 90 Day High Low • Jan 11New 90-day high: Rp1,340The company is up 38% from its price of Rp970 on 14 October 2020. The Indonesian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.
Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improved over the past weekAfter last week's 17% share price gain to Rp1,145, the stock is trading at a trailing P/E ratio of 29.8x, up from the previous P/E ratio of 25.4x. This compares to an average P/E of 21x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 479%.
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to Rp1,035, the stock is trading at a trailing P/E ratio of 27x, down from the previous P/E ratio of 31.8x. This compares to an average P/E of 22x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 481%.
Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 30% share price gain to Rp1,150, the stock is trading at a trailing P/E ratio of 30x, up from the previous P/E ratio of 23.1x. This compares to an average P/E of 20x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 518%.
Is New 90 Day High Low • Dec 08New 90-day high: Rp1,150The company is up 44% from its price of Rp800 on 09 September 2020. The Indonesian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 2.0% over the same period.
Reported Earnings • Nov 08Third quarter 2020 earnings released: EPS Rp19.49The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: Rp73.7b (up 16% from 3Q 2019). Net income: Rp10.4b (up 230% from 3Q 2019). Profit margin: 14% (up from 5.0% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Oct 15Market bids up stock over the past weekAfter last week's 23% share price gain to Rp970, the stock is trading at a trailing P/E ratio of 39.1x, up from the previous P/E ratio of 31.8x. This compares to an average P/E of 15x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 413%.
공시 • Aug 04PT Pyridam Internasional Corporation acquired additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih for approximately IDR 120 billion.PT Pyridam Internasional Corporation acquired additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih for approximately IDR 120 billion on July 10, 2020. PT Pyridam Internasional acquired 160.3 million shares at an offer per share IDR 770.91. Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih sold 36.81 million shares, 61.74 million shares and 61.74 million shares respectively. PT Pyridam Internasional Corporation completed the acquisition of additional 29.96% stake in PT Pyridam Farma Tbk (IDX:PYFA) from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih on July 10, 2020.